Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke.…
4 analysts rate ANVS Buy on consensus.
Consensus price target: $10.50 (+1469.51% upside from $0.67)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Hoffman Michael B director | May 20, 2026 | Purchase | 54,933 | $104.37K |
| Hoffman Michael B director | May 20, 2026 | Purchase | 18,849 | $33.93K |
| Hoffman Michael B director | May 20, 2026 | Purchase | 2,562 | $4.48K |
| Hoffman Michael B director | Apr 2, 2026 | Purchase | 713,800 | $1.5M |
| Hoffman Michael B director | Dec 8, 2025 | Purchase | 15,000 | $63.6K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-28.85M |
| 2024 | $0 | — | $-24.59M |
| 2023 | $0 | — | $-56.2M |
Stock data for ANVS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics